Beyond Dysplasia Grade

The Role of Biomarkers in Stratifying Risk

Research output: Contribution to journalReview article

Abstract

Gastroenterology society guidelines recommend endoscopic surveillance as a means to detect early stage cancer in Barrett's esophagus. However, the incidence of esophageal adenocarcinoma in Western countries continues to increase, suggesting that this strategy may be inadequate. Current surveillance methods rely on the endoscopist's ability to identify suspicious areas of Barrett's esophagus to biopsy, random biopsies, and on the histopathologic diagnosis of dysplasia. This review highlights the challenges of using dysplasia to stratify cancer risk and addresses the development and use of molecular biomarkers and in vivo molecular imaging to detect early neoplasia in Barrett's esophagus.

Original languageEnglish (US)
Pages (from-to)447-459
Number of pages13
JournalGastrointestinal Endoscopy Clinics of North America
Volume27
Issue number3
DOIs
StatePublished - Jul 1 2017

Fingerprint

Barrett Esophagus
Biomarkers
Biopsy
Neoplasms
Molecular Imaging
Gastroenterology
Adenocarcinoma
Guidelines
Incidence

Keywords

  • Barrett's esophagus
  • Biomarker
  • Confocal laser endomicroscopy
  • Dysplasia
  • Fluorescence endoscopy
  • In vivo imaging

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Beyond Dysplasia Grade : The Role of Biomarkers in Stratifying Risk. / Dunbar, Kerry B.; Souza, Rhonda F.

In: Gastrointestinal Endoscopy Clinics of North America, Vol. 27, No. 3, 01.07.2017, p. 447-459.

Research output: Contribution to journalReview article

@article{09168b7c42fa426080e155a9f9c4a65c,
title = "Beyond Dysplasia Grade: The Role of Biomarkers in Stratifying Risk",
abstract = "Gastroenterology society guidelines recommend endoscopic surveillance as a means to detect early stage cancer in Barrett's esophagus. However, the incidence of esophageal adenocarcinoma in Western countries continues to increase, suggesting that this strategy may be inadequate. Current surveillance methods rely on the endoscopist's ability to identify suspicious areas of Barrett's esophagus to biopsy, random biopsies, and on the histopathologic diagnosis of dysplasia. This review highlights the challenges of using dysplasia to stratify cancer risk and addresses the development and use of molecular biomarkers and in vivo molecular imaging to detect early neoplasia in Barrett's esophagus.",
keywords = "Barrett's esophagus, Biomarker, Confocal laser endomicroscopy, Dysplasia, Fluorescence endoscopy, In vivo imaging",
author = "Dunbar, {Kerry B.} and Souza, {Rhonda F.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.giec.2017.02.003",
language = "English (US)",
volume = "27",
pages = "447--459",
journal = "Gastrointestinal Endoscopy Clinics of North America",
issn = "1052-5157",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Beyond Dysplasia Grade

T2 - The Role of Biomarkers in Stratifying Risk

AU - Dunbar, Kerry B.

AU - Souza, Rhonda F.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Gastroenterology society guidelines recommend endoscopic surveillance as a means to detect early stage cancer in Barrett's esophagus. However, the incidence of esophageal adenocarcinoma in Western countries continues to increase, suggesting that this strategy may be inadequate. Current surveillance methods rely on the endoscopist's ability to identify suspicious areas of Barrett's esophagus to biopsy, random biopsies, and on the histopathologic diagnosis of dysplasia. This review highlights the challenges of using dysplasia to stratify cancer risk and addresses the development and use of molecular biomarkers and in vivo molecular imaging to detect early neoplasia in Barrett's esophagus.

AB - Gastroenterology society guidelines recommend endoscopic surveillance as a means to detect early stage cancer in Barrett's esophagus. However, the incidence of esophageal adenocarcinoma in Western countries continues to increase, suggesting that this strategy may be inadequate. Current surveillance methods rely on the endoscopist's ability to identify suspicious areas of Barrett's esophagus to biopsy, random biopsies, and on the histopathologic diagnosis of dysplasia. This review highlights the challenges of using dysplasia to stratify cancer risk and addresses the development and use of molecular biomarkers and in vivo molecular imaging to detect early neoplasia in Barrett's esophagus.

KW - Barrett's esophagus

KW - Biomarker

KW - Confocal laser endomicroscopy

KW - Dysplasia

KW - Fluorescence endoscopy

KW - In vivo imaging

UR - http://www.scopus.com/inward/record.url?scp=85020935108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020935108&partnerID=8YFLogxK

U2 - 10.1016/j.giec.2017.02.003

DO - 10.1016/j.giec.2017.02.003

M3 - Review article

VL - 27

SP - 447

EP - 459

JO - Gastrointestinal Endoscopy Clinics of North America

JF - Gastrointestinal Endoscopy Clinics of North America

SN - 1052-5157

IS - 3

ER -